

## Compositional Determinants of Prion Formation in Yeast<sup>∇</sup>

James A. Toombs, Blake R. McCarty, and Eric D. Ross\*

*Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, Colorado 80523*

Received 24 August 2009/Returned for modification 14 October 2009/Accepted 23 October 2009

**Numerous prions (infectious proteins) have been identified in yeast that result from the conversion of soluble proteins into  $\beta$ -sheet-rich amyloid-like protein aggregates. Yeast prion formation is driven primarily by amino acid composition. However, yeast prion domains are generally lacking in the bulky hydrophobic residues most strongly associated with amyloid formation and are instead enriched in glutamines and asparagines. Glutamine/asparagine-rich domains are thought to be involved in both disease-related and beneficial amyloid formation. These domains are overrepresented in eukaryotic genomes, but predictive methods have not yet been developed to efficiently distinguish between prion and nonprion glutamine/asparagine-rich domains. We have developed a novel *in vivo* assay to quantitatively assess how composition affects prion formation. Using our results, we have defined the compositional features that promote prion formation, allowing us to accurately distinguish between glutamine/asparagine-rich domains that can form prion-like aggregates and those that cannot. Additionally, our results explain why traditional amyloid prediction algorithms fail to accurately predict amyloid formation by the glutamine/asparagine-rich yeast prion domains.**

Amyloid fibers are associated with a large number of neurodegenerative diseases and systemic amyloidoses. Amyloid fibrils are rich in a cross-beta quaternary structure in which  $\beta$ -strands are perpendicular to the long axis of the fibril (8).

[URE3] and [PSI<sup>+</sup>] are the prion (infectious protein) forms of the *Saccharomyces cerevisiae* proteins Ure2 and Sup35, respectively (61). Formation of both prions involves conversion of the native proteins into an infectious, amyloid form. Ure2 and Sup35 have served as powerful model systems for examining the basis for amyloid formation and propagation. Both proteins possess a well-ordered functional domain responsible for the normal function of the protein, while a functionally and structurally separate glutamine/asparagine (Q/N)-rich intrinsically disordered domain is necessary and sufficient for prion aggregation and propagation (4, 26, 27, 52, 53). Both proteins can form multiple prion variants, which are distinguished by the efficiency of prion propagation and by the precise structure of the amyloid core (14, 54).

Five other prion proteins have also been identified in yeast: Rnq1 (13, 46), Swi1 (15), Cyc8 (33), Mca1 (30), and Mot3 (1). Numerous other proteins, including New1, contain domains that show prion activity when inserted in place of the Sup35 prion-forming domain (PFD) (1, 42). Each of these prion proteins contains a Q/N-rich PFD. Similar Q/N-rich domains are overrepresented in eukaryotic genomes (28), raising the intriguing possibility that prion-like structural conversions by Q/N-rich domains may be common in other eukaryotes. However, we currently have little ability to predict whether a given Q/N-rich domain can form prions.

A variety of algorithms have been developed to predict a peptide's propensity to form amyloid fibrils based on its amino acid sequence, including BETASCAN (6), TANGO (17), Zyg-

gregator (51), SALSA (62), and PASTA (55). These algorithms have been successful at identifying regions prone to amyloid aggregation and predicting the effects of mutations on aggregation propensity for many amyloid-forming proteins. However, they have generally been quite ineffective for Q/N-rich amyloid domains such as the yeast PFDs. For example, using the statistical mechanics-based algorithm TANGO (17), which predicts aggregation propensity based on a peptide's physicochemical properties, Lindling et al. found that the Sup35 and Ure2 PFDs both completely lack predicted  $\beta$ -aggregation nuclei (24). Similarly, yeast PFDs are generally lacking in the hydrophobic residues predicted by algorithms such as Zygggregator to nucleate amyloid formation.

Why are these algorithms so effective for many amyloid-forming proteins but not for yeast PFDs? For most amyloid proteins, amyloid formation is driven by short hydrophobic protein stretches, and increased hydrophobicity is correlated with an increased amyloid aggregation propensity (34). In contrast, the yeast PFDs are all highly polar domains, due largely to the high concentration of Q/N residues and the lack of hydrophobic residues. High Q/N content is clearly not a requirement for a domain to act as a prion in yeast, since neither the mammalian prion protein PrP nor the *Podospora anserina* prion protein HET-s is Q/N rich, yet fragments from both proteins can act as prions in yeast (49, 50). However, the significant compositional differences between the yeast PFDs and most other amyloid/prion proteins suggest that there may be two distinct classes of amyloid-forming proteins driven by different types of interactions. Specifically, Q/N residues, which are predicted to have a relatively low amyloid propensity in the context of hydrophobic amyloid domains (34), may promote amyloid formation when present at sufficiently high density. Stacking of Q/N residues to form polar zippers has been proposed to stabilize amyloid fibrils (35). Consistent with this hypothesis, mutational studies of Sup35 indicate that Q/N residues are critical for driving [PSI<sup>+</sup>] formation (12), and expanded poly-Q or poly-N tracts are sufficient to drive amyloid aggregation (36, 63). Therefore, this paper examines the se-

\* Corresponding author. Mailing address: Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523. Phone: (970) 491-0688. Fax: (970) 491-0494. E-mail: eric.ross@colostate.edu.

<sup>∇</sup> Published ahead of print on 2 November 2009.



Saccharomyces Genome Database (<http://www.yeastgenome.org/>). For the plotting of  $OR_{PFD}$  versus the observed odds ratio ( $OR_{obs}$ ), for amino acids that were completely absent from the PFD,  $f_{pfd}$  was set as 0.5 divided by the length of the PFD to avoid zero values in the logarithm.

**Calculating prion propensity and disorder.** Proteins were scanned using an 11- or 41-amino-acid window size. Prion propensities were calculated as the sum of  $\ln(OR_{obs})$  across the window. When clusters of prolines (defined as two or more prolines separated by no more than one intervening residue) were present within a window, only the first proline in the cluster was counted in the prion propensity calculations. For plotting, the position of the window was defined based on the central amino acid. For windows near the termini of proteins (such that there are fewer than 20 amino acids on the C- or N-terminal side of the central amino acid), the denominator was adjusted accordingly in calculating the average values. In averaging consecutive windows, for windows near the termini, windows of less than 41 amino acids were weighted in the average according to their length. Randomly selected proteins were chosen from all annotated open reading frames using the Excel software program's random number generating function. Randomly selected open reading frames are *RPS17A*, *YGR235C*, *YPRI*, *NIP100*, *ERG12*, *ARPI0*, *YAR003W*, *ECM7*, *YNL083W*, *YLR247C*, *YDR275W*, *YOR087W*, *SEC8*, *ALG6*, *YBR226C*, *ROM1*, *MAL33*, *MYO3*, *SFII*, and *YJL039C*.

**Distribution of proline residues.** If proline residues were randomly distributed in a sequence, the probability that one of the two residues immediately preceding or following a given proline would be another proline is equal to 1 minus the prevalence of nonproline residues within the remainder of the sequence raised to the fourth power. The expected number of clustered prolines within each group (prion, prion-like, and nonprion) was calculated as the sum of the predicted number of clustered prolines for each member of the group. Using chi-square analysis, this predicted value was compared to the observed fraction of prolines for which one of the two subsequent residues was also a proline.

## RESULTS

**Mapping the Sup35-27 prion domain.** Randomizing the order of the amino acids in the Sup35 PFD while maintaining amino acid composition does not prevent  $[PSI^+]$  formation (41). We used one of these scrambled versions of Sup35, Sup35-27, as a template for mutagenesis. Sup35-27 was chosen for three reasons. First, wild-type Sup35 very rarely forms prions without overexpression, making it difficult to isolate prion-forming clones upon mutagenesis. Sup35-27 forms prions de novo with greater efficiency than wild-type Sup35, allowing for isolation of a broader range of prion-forming clones. Second, any specific prion-promoting primary sequence elements or any binding sites within the PFD for interacting proteins were likely disrupted by randomization, simplifying interpretation of the results of our library screen. Finally, solid-state nuclear magnetic resonance suggests that Sup35-27 and wild-type Sup35 form fibrils that are structurally similar (45).

To identify ideal regions of the Sup35-27 PFD to target for mutagenesis, we mapped the prion-promoting regions of the PFD through deletion analysis. Prion formation was detected by monitoring nonsense suppression of the *ade2-1* allele (11). *ade2-1* mutants are unable to grow without adenine and form red colonies when grown in the presence of limiting adenine. Sup35 is a translation termination factor.  $[PSI^+]$  formation inactivates Sup35, resulting in increased read-through of stop codons (23), allowing *ade2-1*  $[PSI^+]$  cells to grow without adenine and form white colonies on limiting adenine.

*SUP35-27* carrying various deletions was expressed as the sole copy of *SUP35* in the cell, and  $Ade^+$  colony formation was monitored. To confirm that  $Ade^+$  colony formation was a result of  $[PSI^+]$  formation, we tested individual  $Ade^+$  colonies to determine whether the  $Ade^+$  phenotype was curable by guanidine. Growth on medium containing low concentrations of guanidine cures  $[PSI^+]$  (57) by inhibiting Hsp104p (18, 20).




FIG. 1. Deletion mapping of the Sup35-27p PFD. (A) Sequence of Sup35-27, with regions mutated in libraries 1 and 2 shown in bold italics. (B) Ten-amino-acid segments were deleted from the Sup35-27p PFD. Deletion mutants were expressed as the sole copy of *SUP35* in the cell. All mutants produced stable curable prions. “+++” indicates that more than 4  $Ade^+$  colonies per  $10^6$  cells were detected; “++” indicates 1 to 4  $Ade^+$  colonies per  $10^6$  cells; “+” indicates fewer than 1  $Ade^+$  colony per  $10^6$  cells.

We found that 20 amino acids could be removed from either end of the PFD while retaining  $[PSI^+]$  formation (Fig. 1). Deletion analysis of the PFD showed various levels of importance for different regions within the prion core (Fig. 1B), with the region of amino acids 31 to 50 being particularly sensitive to deletion.

**Random mutagenesis of *SUP35-27*.** Based on our deletion data, we targeted amino acids 31 to 50 of Sup35-27 for random mutagenesis. In preliminary experiments, we tested the optimal size of the mutated region. Mutagenesis of 12 amino acids almost entirely eliminated prion formation, while mutagenesis of either four or eight amino acids still allowed an easily detectable level of prion formation (data not shown). Because a larger region of mutagenesis would provide more data and increase the stringency of selection, eight amino acids were mutated in all subsequent experiments. Amino acids 39 to 46 of the PFD were targeted for random mutagenesis because these residues lie within the region that seems critical for prion formation and because the composition of this region is fairly representative of the Sup35 PFD.

We used an oligonucleotide-based mutagenesis approach. An oligonucleotide was designed that annealed to the regions flanking codons 39 to 46 but in which the codons 39 to 46 were replaced with the sequence  $(NNB)_8$ , where N represents any of the four nucleotides and B represents any nucleotide except adenine. Excluding adenine from the final position prevents insertion of two of the three stop codons without excluding any amino acids. This oligonucleotide was used to build a library of



randomly mutated versions of *SUP35-27*. The library was transformed into yeast cells in which the sole copy of *SUP35* was expressed from a plasmid. Using plasmid shuffling, wild-type *SUP35* was replaced with the random library.

To remove any Sup35 mutants that might result in nonsense suppression, each clone was screened for Sup35 activity using the *ade2-1* allele. All library clones were spotted onto medium containing limiting adenine and onto medium lacking adenine. Colonies that grew red on limiting adenine and did not grow without adenine were pooled. To prevent rare strong prion-forming clones from dominating selection, clones were pooled into minilibraries consisting of approximately 50 clones. With this size of minilibrary, we were able to isolate a single prion-forming clone from about half of the minilibraries. *SUP35* was sequenced from individual library clones prior to prion selection to generate a naive library data set (Table 1).

Minilibraries were plated on medium lacking adenine to select for  $[PSI^+]$  formation. To distinguish  $Ade^+$  cells resulting from  $[PSI^+]$  formation from those resulting from DNA mutation, we tested individual  $Ade^+$  colonies to determine whether the  $Ade^+$  phenotype was curable by guanidine. Cells were grown on YPD with and without guanidine and then restreaked on YPD to test for loss of the  $Ade^+$  phenotype (data not shown). *SUP35* was sequenced from cells that stably maintained the  $Ade^+$  phenotype on YPD but lost it after growth on YPD plus guanidine. We isolated 27 such stable prion isolates from an initial library of 3,016 clones (Table 1).

**Compositional biases among the prion-forming isolates.** For each amino acid, the observed odds ratio ( $OR_{obs}$ ), representing the degree of over/underrepresentation of the amino acid within the prion-forming isolates, was determined (Table 2).  $OR_{obs}$  was defined as

$$OR_{obs} = [f_p / (1 - f_p)] / [f_n / (1 - f_n)] \quad (2)$$

where  $f_p$  is the per-residue frequency of the amino acid among the prion-forming isolates and  $f_n$  is the per-residue frequency of the amino acid among the naive library.

A statistically significant ( $P < 0.05$ ) overrepresentation of Phe, Ile, and Val was seen among the prion-forming isolates, and a statistically significant bias was seen against Asp, Lys, and Pro (Table 2). Other, more subtle biases were seen that were not statistically significant due to the limits of sample size. Grouping of similar amino acids allows detection of more subtle biases by effectively increasing the sample size. We observed a strong bias in favor of nonpolar amino acids and aromatic amino acids among the prion-forming library, while charged residues were underrepresented (Table 2). Surprisingly, Q/N residues were not statistically significantly overrepresented.

**Yeast PFDs are biased toward the most amyloidogenic disorder-promoting residues.** Consistent with our experimental data, charged residues are strongly underrepresented in yeast PFDs; however, in contrast with our data, hydrophobic residues are also strongly underrepresented and Q/N residues are highly overrepresented in yeast PFDs (19, 42). Consequently, there is almost no correlation between the amino acids that most strongly promote prion formation and the compositions of the Ure2, Sup35, and Rnq1 PFDs (Fig. 2A to C). A similar lack of correlation is seen for the other newly discovered PFDs

TABLE 1. Mutated sequences from selected and unselected libraries

Library 1 <sup>a</sup>		Library 2 <sup>b</sup>	
$[PSI^+]$ isolate	Naive library	$[PSI^+]$ isolate	Naive library
VNIFPYYN	TDPWVPH	FANHAHWV	SVSDHTNP
VTSGSYNT	NPEVNPAN	GTTYAPLF	KGRVSGPE
ASNVMNC	THHSHTLP	WNAFSTYS	ATSPVPRH
AHTNMIV	YLPFMDTP	HTVHHIYP	YEYSPLOH
YNSVSNML	PPIVKPRT	LNTFFHSY	TMTDLPYL
FSIYMPYK	VDDRHMFS	DIMTNNAE	ESILWASQ
LLVHSNAI	CKSVCNFD	SQDYSSYD	FTRAKSRT
WGARQFNI	GISTRSQE	CINTGLWL	TTSYHPRL
VTTDILAM	VLSKNRNL	HLHMSMLS	VAHCRHPL
RRDYLTRF	LRDPDTCS	DRHYFAGS	SSTLLDPK
STVICGVI	RKATDLFP	GGPIFNK	IETHFTLS
IHFWRAP	TAYVRHID	SFMAVETR	APHGLGPT
HSNVSVIH	DRYKGGPH	TWDGIGYR	RCSDSQGV
TWAPIMVY	DPNAALVF	SPPFETSP	VHHPVST
MFQHGIGV	HHPLFIH	GVNTHTSY	HPIMSSLS
TRIWNFSG	TLARRDPP	SIHMRVSS	LGPVHYRN
YHSVEFRI	PNASGIHY	HNDRTAFM	SMHNGTHR
TTVNHFFN	ADSASNAS	PQNQTWAD	DGPTYDWT
GSLSLQYF	NGPAYPLA	PDYFFHPT	PYKAATRN
IFDIANHS	SVNPALYR	HVPSPAHO	PTYNDPST
LQPCYCSR	SGVSTAVR	SDSHHFWP	LSQSYVQE
MLSSNFIH	LNRTLRN	TSNTIIRA	YDSGTPPK
SSGPLNFI	IVPRNVNC	DCLGYPLG	SQQRFNPT
CLSPAECR	NISPFKSD	SMHNGTHR	HRDNCRTR
QFVARVFR	MTQNPHIF	ESILWASQ	PPQAVYPP
LKSVITWN	LSARPLGH	PRLTNHSS	QHASGRDG
SVHVNSTS	LGNPTFHY	FWMQRNSC	QTRFYGIH
	AQDSHPDI	SFSYVTFP	QTTAIIHA
	NNPQYLK	CQINWRTA	PHEAVSSC
	DERPWCE	GPPFPQGN	RRHYAPSI
	GPTMNNRD	VASWASVG	KYMYHANM
	THRHNKHR	YREGDNLW	LADSNTPR
	KGSPSTPT	HTLVFNDR	SLAAPRDN
	EAPSKSAQ		FWIDGSAD
	RPERRSNP		DRHYFAGS
	ICWHITEPY		IRTHMSSK
	CIKHINSI		ARNMTRYL
	PVPSSSQP		RAYDILPV
	GANSAITN		NEDPGTDT
	SHLWRRNR		SRSIRYDN
	DSHTGTPR		SQDYSSYD
	STVPPPHH		
	VNCARGTA		
	QVASQNGR		
	SSNKFMT		
	GFTKALPG		
	ALSSRQWS		
	IDKNLMSH		
	CFLRSYMG		
	VALIPKTA		
	HNLANHSH		
	KMTTNTKH		

<sup>a</sup> Library 1, mutated amino acids 39 to 46 of the Sup35-27 PFD.

<sup>b</sup> Library 2, mutated amino acids 55 to 62 of the Sup35-27 PFD.

(Mot3, Mca1, Swi1, and Cyc8; data not shown), although the exact boundaries of these PFDs have not been clearly defined, complicating their analysis.

Intrinsic disorder seems to explain the disconnect between the residues that promote prion formation and those that are actually present in PFDs. A key feature of the yeast PFDs is that they are intrinsically disordered (37, 43). When we consider only those residues most strongly associated with intrinsic

TABLE 2. Library 1 amino acid representation

Amino acid(s)	Frequency <sup>a</sup>		Odds ratio <sup>b</sup>	ln (OR <sub>obs</sub> )	P value <sup>c</sup>
	Selected [PSI <sup>+</sup> ] library	Unselected naive library			
Phenylalanine (F)	0.075	0.032	2.31	0.84	0.040
Isoleucine (I)	0.102	0.045	2.26	0.81	0.015
Valine (V)	0.102	0.045	2.26	0.81	0.015
Tyrosine (Y)	0.054	0.025	2.18	0.78	0.099
Methionine (M)	0.038	0.020	1.96	0.67	0.19
Tryptophan (W)	0.024	0.012	1.95	0.67	0.32
Cysteine (C)	0.033	0.022	1.52	0.42	0.43
Serine (S)	0.125	0.109	1.14	0.13	0.68
Asparagine (N)	0.096	0.089	1.08	0.080	0.88
Glutamine (Q)	0.024	0.022	1.07	0.069	1.00
Glycine (G)	0.038	0.040	0.96	-0.039	1.00
Leucine (L)	0.059	0.061	0.96	-0.040	1.00
Threonine (T)	0.069	0.078	0.89	-0.12	0.75
Histidine (H)	0.059	0.078	0.76	-0.28	0.50
Alanine (A)	0.042	0.072	0.67	-0.40	0.38
Arginine (R)	0.054	0.081	0.67	-0.41	0.31
Glutamic acid (E)	0.009	0.017	0.55	-0.61	0.51
Proline (P)	0.038	0.127	0.30	-1.20 <sup>d</sup>	0.002
Aspartic acid (D)	0.014	0.051	0.28	-1.28	0.041
Lysine (K)	0.009	0.045	0.21	-1.58	0.028
Groups					
Aromatic (FWY)	0.144	0.067	2.32		0.002
Hydrophobic (FILMV)	0.347	0.195	2.20		3.0 × 10 <sup>-05</sup>
Charged (DEKR)	0.083	0.183	0.41		8.8 × 10 <sup>-04</sup>
Positive (KR)	0.060	0.118	0.48		0.024
Negative (DE)	0.023	0.065	0.34		0.034
Polar (NQHST)	0.343	0.346	0.98		0.92
Q/N	0.111	0.103	1.08		0.79

<sup>a</sup> [PSI<sup>+</sup>] values represent the frequency of occurrence of the amino acid among the prion-forming isolates; naive values represent the frequency of occurrence of the amino acid among the unselected clones.

<sup>b</sup> Odds ratios (OR<sub>obs</sub>) were calculated using equation 2.

<sup>c</sup> P value is based on the 2-tailed Fisher exact probability test.

<sup>d</sup> When multiple consecutive prolines are separated by less than one residue, a value of zero is used for ln (OR<sub>obs</sub>) for each proline after the first in the cluster.

disorder—Lys, Pro, Gly, Arg, Asn, Gln, Ser, Glu, and Asp (58)—there is excellent correlation between our experimentally determined prion propensities and the compositions of the yeast PFDs (Fig. 2D to F). These disorder-promoting residues are highly overrepresented in the Sup35, Rnq1, and Ure2 PFDs ( $P < 0.0001$  for each PFD), accounting for 75%, 76%, and 79% of the amino acids in the PFDs, respectively, and are similarly overrepresented in all other known yeast PFDs ( $P < 0.01$  for each PFD). Thus, the yeast PFDs are biased toward residues that balance disorder propensity and prion propensity.

**Characteristics that promote prion formation.** The aggregation propensity for mutants of various non-Q/N-rich amyloidogenic polypeptides is positively correlated with hydrophobicity and  $\beta$ -sheet propensity and negatively correlated with charge and  $\alpha$ -helix propensity (34). Consistent with these predictions, hydrophobicity (39) and  $\beta$ -sheet propensity (48) were significantly greater among the prion-forming clones than among the naive library (for the  $\beta$ -sheet propensity scale, lower

values represent increased  $\beta$ -sheet propensity), and the absolute value of the net charge was significantly lower (Table 3). Surprisingly,  $\alpha$ -helix propensity (22) was modestly greater among the prion-forming clones. However, this can be attributed almost entirely to a bias against prolines among the prion-forming clones; when prolines are excluded from the calculation, the average per-residue  $\alpha$ -helix propensity is statistically indistinguishable between the naive and prion-forming libraries.

We examined the degree to which over/underrepresentation of each amino acid among the prion-forming isolates could be explained based on the physical properties of the amino acid. For each amino acid, the natural log of the amino acid's odds ratio was plotted as a function of various physical properties. Hydrophobicity and  $\beta$ -sheet propensity were both positively correlated with ln (OR<sub>obs</sub>) (Fig. 3A and B). In contrast, no significant correlation was seen between an amino acid's  $\alpha$ -helix propensity and its odds ratio (Fig. 3C).

Assuming that the effects of hydrophobicity and  $\beta$ -sheet propensity are additive, we combined these properties for each amino acid to predict an estimated odds ratio (OR<sub>est</sub>):

$$\ln(\text{OR}_{\text{est}}) = A(H) + B(P_{\beta}) \quad (3)$$

where  $H$  and  $P_{\beta}$  are the hydrophobicity and  $\beta$ -sheet propensity of the amino acid, respectively. As a starting estimate for  $A$  and  $B$ , we used the slopes of Fig. 3A and B (0.25 and -2.26, respectively). This function was used to calculate the OR<sub>est</sub> for each amino acid. The estimated odds ratio showed a strong correlation with the observed odds ratio ( $r^2 = 0.74$ ) (Fig. 3D). The observed slope was 0.71; it is not surprising that it would be less than 1, since hydrophobicity and  $\beta$ -sheet propensity are not truly independent. Based on the curve fit,  $A$  and  $B$  in equation (3) were modified, yielding the following equation, which predicts the prion propensity of each amino acid within experimental error (Fig. 3D):

$$\ln(\text{OR}_{\text{pred}}) = 0.18(H) + 1.61(P_{\beta}) + 0.66 \quad (4)$$

**Similar, but weaker, biases are seen at a second position.** To determine whether different regions of the PFD show different amino acid biases, we generated a second library (library 2) targeted to amino acids 55 to 62—a region that appears to be less critical for [PSI<sup>+</sup>] formation based on our deletion mapping. Using the same methods as for library 1, we screened 1,033 clones and found 33 capable of forming prions—a success rate of 3.19%, versus 0.895% for library 1. This nearly 4-fold increase in the prion formation rate highlights the lesser importance of amino acids 55 to 62 for prion formation.

Both individual amino acids and groups of amino acids show general biases in library 2 (Table 4) similar to those in library 1 (Table 2). There was a strong correlation between the odds ratios for each amino acid for library 1 and library 2 (Fig. 4A). This is even more apparent when amino acids are considered in groups (hydrophobic, charged, polar, and aromatic), where the correlation plot of the odds ratios for the two libraries has an  $r^2$  value of 0.98 (Fig. 4B). For both plots, the slope is approximately 0.65, indicating that although similar amino acids are selected for among the prion-forming clones in the two libraries, the strength of selection is stronger for library 1 than for library 2.




FIG. 2. The Ure2, Sup35, and Rnq1 PFDs are biased toward amyloidogenic disorder-promoting residues. (A to C) Relationship between the degree to which an amino acid promotes prion formation and the amino acid's prevalence within yeast PFDs.  $\ln(\text{OR}_{\text{obs}})$  (from Table 2) was plotted versus  $\ln(\text{OR}_{\text{PFD}})$  (as calculated in equation 1) for the prion domain from Ure2 (A), Sup35 (B), or Rnq1 (C). (D to F) Analysis only of the disorder-prone amino acids Lys, Pro, Gly, Arg, Asn, Gln, Ser, Glu, and Asp.

**Identification of regions sensitive to mutagenesis.** We hypothesized that the differential sensitivity to mutation seen in the regions targeted for mutagenesis in libraries 1 and 2 could be explained by differences in the prion propensity of the two regions. We scanned the Sup35-27 PFD using a window size of 11 amino acids. For each window, we calculated the predicted prion potential as the sum of the  $\ln(\text{OR}_{\text{obs}})$  (Fig. 5A), based on the experimentally obtained values from library 1 (Table 2). These plots predict the region targeted in library 1 to have relatively high prion propensity and the region targeted in library 2 to have low prion propensity. These results are consistent with the greater sensitivity to deletion (Fig. 1) and

stringency of selection (Fig. 4) seen for library 1 than for library 2.

Similar analysis of the wild-type Sup35 PFD reveals two peaks in prion potential, spanning amino acids 8 to 35 and 44 to 61 (Fig. 5B). This nicely coincides with analysis of Sup35 showing that (i) mutations that block  $[\text{PSI}^+]$  propagation specifically localize to amino acids 8 to 34 of the PFD (12); (ii) the amyloid core, as defined by hydrogen-deuterium exchange, spans either the first 40 or first 70 amino acids of the PFD, depending on the structural variant analyzed (54); (iii) the minimal fragment required to efficiently induce  $[\text{PSI}^+]$  formation is amino acids 1 to 64 (32); and (iv) depending on the prion variant, amino acids 7 to 21, 9 to 37, or 5 to 52 are critical to the integrity of the Sup35 amyloid core (7).

**Predicting prion propensity based on composition.** A key question is whether results from mutagenesis of small regions can be extrapolated to predict prion formation by larger PFDs. Scanning of 20 randomly selected non-Q/N-rich proteins using an 11-amino-acid window size (Fig. 6A, red circles) shows that regions with prion propensity equal to or greater than that of the Sup35 and Ure2 PFDs (Fig. 6A, blue circles) are common. Although many of these regions are predicted using the FoldIndex software program (38) to be natively folded (in contrast to the intrinsically disordered Sup35 and Ure2 PFDs), within these randomly selected proteins are disordered regions with a prion propensity comparable to that of the Sup35 and Ure2 PFDs (Fig. 6A). Therefore, scanning with an 11-amino-acid window size did not allow effective identification of these PFDs.

TABLE 3. Physical properties of prion-forming isolates from library 1

Property	Mean value $\pm$ SEM for naive library	Mean value $\pm$ SEM for prion-forming isolates	$P$ value
Hydrophobicity <sup>a</sup>	$-4.30 \pm 0.72$	$0.02 \pm 0.75$	$1.8 \times 10^{-4}$
$\beta$ -Sheet propensity <sup>b</sup>	$3.18 \pm 0.10$	$2.34 \pm 0.09$	$3.5 \times 10^{-7}$
$\alpha$ -Helix propensity <sup>c</sup>	$1.35 \pm 0.17$	$0.73 \pm 0.18$	0.028
Charge <sup>d</sup>	$0.88 \pm 0.11$	$0.44 \pm 0.12$	0.016

<sup>a</sup> From reference 39. Higher values represent greater hydrophobicities. For each naive or prion-forming isolate, the sum of the hydrophobicities of each residue within the mutagenized region was calculated. Data are the average sum per construct for the respective libraries. Standard errors are indicated.

<sup>b</sup> From reference 48. Higher values represent lower  $\beta$ -sheet propensities.

<sup>c</sup> From reference 22. Higher values represent lower  $\alpha$ -helix propensities.

<sup>d</sup> The absolute value of the net charge of the mutated region.




FIG. 3. Relationship between the properties of an amino acid and its prevalence among library 1 prion-forming isolates.  $\ln(OR_{obs})$  for each amino acid in library 1 (from Table 2) plotted versus hydrophobicity (A),  $\beta$ -sheet propensity (B) (lower values represent greater  $\beta$ -sheet propensities),  $\alpha$ -helix propensity (C) (lower values represent greater  $\alpha$ -helix propensities), or  $\ln(OR_{est})$  (D).  $P$  values were calculated by Spearman's rank correlation. Error bars represent 95% confidence intervals.

We hypothesized that yeast PFDs would be characterized by extended regions of disorder and a high prion propensity. Therefore, to reduce noise in scanning of entire proteins, we expanded our window size to 41 amino acids, which roughly correlates with the minimal fragment required to induce yeast prion formation (41). When the same 20 randomly selected proteins were scanned using a 41-amino-acid window size, regions of high prion propensity were consistently predicted to have a high FoldIndex order propensity; by contrast, the Sup35 and Ure2 PFDs are predicted to have a positive prion propensity and a negative FoldIndex (Fig. 6B). Thus, these PFDs are unique in having extended segments that are both prion prone and intrinsically disordered.

To determine whether a combination of prion propensity and disorder could be used to distinguish between prion-forming and non-prion-forming Q/N-rich domains, we utilized the massive data set generated by Alberti et al. (1). They tested the 100 proteins with greatest compositional similarity to the Sup35, Ure2, Rnq1, and New1p PFDs (Mot3, Cyc8, Mca1, and Swi1 had not yet been published) in four different assays for

prion-like activity. All of these domains were highly enriched in Q/N residues. Eighteen proteins showed prion-like activity in all assays (including four known prion proteins; Mot3, Cyc8, and Mca1 scored positive only in a subset of the tests), while 18 did not show activity in any of the assays. We scanned each of these 36 potential PFDs, as well as each of the known PFDs, using a 41-amino-acid window size, calculating the average FoldIndex order propensity and the prion propensity, with one modification. In domains with prion-like activity, when proline residues are present, they disproportionately occur in clusters; in contrast, such clusters are underrepresented in Q/N-rich domains that lack prion-like activity (Table 5). Likewise, Alberti et al. reported that the spacing of proline residues affected the prion propensity, with more-dispersed spacing correlating with a decreased prion propensity (1). This makes sense; because prolines are known  $\beta$ -sheet breakers (9, 10), a cluster of prolines will disrupt the potential for  $\beta$ -sheet formation only at a single location, while the same number of proline residues dispersed throughout a sequence would result in multiple separate locations where  $\beta$ -strands could be disrupted.



TABLE 4. Library 2 amino acid representation

Amino acid(s)	Frequency <sup>a</sup>		Odds ratio <sup>b</sup>	P value <sup>c</sup>
	Selected [PSI <sup>+</sup> ] library	Unselected naive library		
Tryptophan (W)	0.042	0.009	4.71	0.013
Phenylalanine (F)	0.064	0.021	3.16	0.011
Asparagine (N)	0.068	0.040	1.77	0.14
Methionine (M)	0.030	0.021	1.43	0.60
Glycine (G)	0.057	0.046	1.26	0.58
Isoleucine (I)	0.038	0.030	1.25	0.65
Cysteine (C)	0.015	0.012	1.25	1.00
Histidine (H)	0.080	0.070	1.15	0.75
Valine (V)	0.038	0.037	1.04	1.00
Glutamic acid (E)	0.023	0.024	0.93	1.00
Serine (S)	0.110	0.119	0.91	0.80
Threonine (T)	0.087	0.095	0.91	0.78
Alanine (A)	0.057	0.064	0.88	0.73
Leucine (L)	0.045	0.052	0.87	0.85
Glutamine (Q)	0.030	0.037	0.82	0.82
Tyrosine (Y)	0.049	0.064	0.76	0.48
Proline (P)	0.072	0.095	0.74	0.37
Aspartic acid (D)	0.045	0.067	0.66	0.29
Arginine (R)	0.045	0.076	0.58	0.17
Lysine (K)	0.004	0.021	0.17	0.081
<b>Groups</b>				
Aromatic (FWY)	0.155	0.095	1.76	0.031
Hydrophobic (FILMV)	0.216	0.162	1.43	0.11
Charged (DEKR)	0.117	0.189	0.57	0.023
Positive (KR)	0.049	0.098	0.48	0.029
Negative (DE)	0.068	0.091	0.73	0.36
Polar (NQHST)	0.375	0.360	1.07	0.73
Q/N	0.098	0.076	1.32	0.38

<sup>a</sup> The [PSI<sup>+</sup>] value represents the frequency of occurrence of the amino acid among the prion-forming isolates; the naive value represents the frequency of occurrence of the amino acid among the unselected clones.

<sup>b</sup> Odds ratios were calculated using equation 2.

<sup>c</sup> P value is based on the 2-tailed Fisher exact probability test.





FIG. 4. Library 2 shows biases similar to but weaker than those of library 1.  $\ln(\text{OR}_{\text{obs}})$  from library 1 was plotted versus  $\ln(\text{OR}_{\text{obs}})$  from library 2 for each amino acid (A) or for groups of amino acids (B). Hydrophobic residues were defined as Phe, Ile, Leu, Met, and Val. Polar amino acids were defined as Ser, Thr, His, Gln, and Asn. Charged amino acids are Asp, Glu, Lys, and Arg. Aromatic amino acids were defined as Trp, Tyr, and Phe. Error bars represent 95% confidence intervals.




FIG. 5. Predicted prion-prone regions. The PFD of Sup35-27 (A) or wild-type Sup35 (B) was scanned using an 11-amino-acid window size. At each position within the prion domains, the sum of  $\ln(\text{OR}_{\text{obs}})$  for the indicated amino acid and the five amino acids on either side was calculated to determine the prion propensity of the window. Regions mutated in libraries 1 and 2 are indicated.

Therefore, multiple consecutive prolines were treated as a single proline in our prion propensity calculations.

The profiles of the domains found to form prion-like aggregates were generally different from those that did not show prion activity. All of the known PFDs except that of Cyc8 have






FIG. 6. Predicting prion propensity for Q/N domains. (A and B) Prion propensity and FoldIndex order predictions for 20 randomly selected open reading frames (red) (see Materials and Methods for gene names) and the PFDs of Sup35p and Ure2p (blue). Proteins/PFDs were scanned using an 11-amino-acid (A) or 41-amino-acid (B) window size. For each window, the predicted prion propensity (calculated as the average  $\ln(\text{OR}_{\text{obs}})$  across the window) versus the predicted FoldIndex order propensity (where negative values are associated with disorder) was plotted. (C and D) Prion propensity and order prediction for Q/N-rich domains with prion-like activity (circles), for Q/N-rich domains shown by Alberti et al. (1) to lack prion-like activity in four prion assays (shaded triangles), for the HET-s PFD (blue square), and for human PrP (yellow square). Q/N-rich domains with prion-like activity include both known PFDs (shaded circles) and domains shown by Alberti et al. to have prion-like activity in four prion assays (circles with red slashes). For each potential PFD, the average prion propensity and average disorder are plotted for the 41 consecutive 41-amino-acid windows with maximum average predicted prion propensity (C) or the 11-amino-acid window with maximum prion propensity (D). The region of the graph identified as prion prone in panel C is shaded.

extended regions that are predicted to be both disordered and prion prone (Fig. 7A, blue circles), while similar regions are extremely rare in the nonprion domains (Fig. 7A, red circles). Similarly, each of the domains shown by Alberti et al. to have prion-like activity in all four assays (1) had multiple consecu-

tive windows that were both disordered and prion prone (Fig. 7B); by contrast, such regions are rare in peptides that lack prion activity (Fig. 7C).

To determine whether the presence of consecutive prion-prone windows could be used to distinguish between prion-forming and non-prion-forming Q/N domains, we identified for each peptide the 41 consecutive 41-amino-acid windows that had the maximum average predicted prion propensity. By averaging 41 consecutive windows, we are effectively calculating prion propensity for 81 consecutive amino acids (40 on each side of a central residue); however, because the central residue is present in each 41-amino-acid window while outer residues are present only in a subset of the windows, the weighting of each residue is inversely proportional to its distance from the central residue. Therefore, this method incorporates the idea that the sequence requirements for prion formation are more flexible further from the core of the PFD. When the prion propensity for the optimal region of each peptide was plotted versus the average FoldIndex value, a clear difference was seen between those peptides that showed prion-like activity and those that did not (Fig. 6C). If the criterion for

TABLE 5. Clustering of prolines in prion-forming Q/N-rich domains

Group	No. of prolines in clusters <sup>a</sup>		<i>P</i> value <sup>e</sup>
	Predicted <sup>b</sup>	Observed	
Prion-like domains <sup>c</sup>	50.8	68	0.0054
Non-prion Q/N domains <sup>d</sup>	39.0	25	0.0073

<sup>a</sup> That is, prolines for which one of the two residues following the proline or one of the two residues preceding it is also a proline.

<sup>b</sup> Predictions are based on the total number of proline residues within each potential PFD, assuming that the proline residues are randomly distributed.

<sup>c</sup> Includes both the 18 Q/N-rich domains shown by Alberti et al. to have prion-like activity in four different assays (1) and the other known yeast PFDs (Mot3, Cyc8, and Mcal).

<sup>d</sup> The 18 Q/N-rich domains shown by Alberti et al. to lack prion-like activity in all four assays (1).

<sup>e</sup> *P* value is calculated by chi-square analysis.




FIG. 7. Prion propensity maps. (A) Scanning of known yeast prion proteins. Each of the yeast prion proteins was scanned using a 41-amino-acid window size, calculating for each window the average FoldIndex order propensity and prion propensity. Prion propensities were calculated based on the average  $\ln(OR_{obs})$  for each amino acid in the window. The prion domains of each protein are shown in blue and the nonprion domains in red. (B) Scan of Q/N-rich domains tested by Alberti et al. that showed prion-like activity in all assays. (C) Scan of Q/N-rich domains tested by Alberti et al. that lacked prion-like activity in all assays. (D) Scan of the HET-s PFD and the human prion protein PrP.

a PFD is defined as a region of negative FoldIndex order propensity that has an average prion propensity greater than 0.05 (the shaded area in Fig. 6C), 17 of the 18 peptides lacking prion-like activity (shaded triangles) are properly scored as nonprion; in contrast, 16 of 18 domains shown by Alberti et al. to have prion-like activity in all four assays (circles with slashes through them) and six of the seven known yeast PFDs (shaded circles) are correctly scored as prion positive. Additionally, none of the randomly selected proteins from Fig. 6A had any regions that score as prion prone by these criteria. Although the mammalian prion protein PrP does contain a short region that has negative FoldIndex order propensity and positive predicted prion propensity spanning windows centered on residues 143 to 174 (Fig. 7D), neither PrP nor the *Podospora anserina* prion protein HET-s scores as prion prone by our criteria (Fig. 6C). This is not surprising, since neither is particularly Q/N rich and therefore they are likely to be more accurately predicted by algorithms designed for non-Q/N-rich amyloid proteins.

When potential PFDs were scanned using an 11-amino-acid window size, with the window of maximum prion propensity plotted for each protein, there is considerable overlap between those proteins that showed prion-like activity and those that did not (Fig. 6D). Therefore, yeast PFDs are characterized not by short, highly prion-prone segments but instead by large disordered regions of modest prion propensity.

**Compositional similarity to known PFDs is a poor predictor of a Q/N-rich domain's prion propensity.** Various algorithms to identify novel PFDs based on compositional similarity to known PFDs have been designed to look for some combination of the following: (i) high Q/N content (19, 28, 42, 46), (ii) a bias against charged residues (19, 28, 42), (iii) a bias against hydrophobic residues (19), and (iv) subsidiary biases for glycine, serine, or tyrosine (19). However, when the Q/N-rich proteins with and without prion-like activity are compared, little or no difference is seen for any of these groups of amino acids (Fig. 8A). Therefore, although these biases have proven effective for identifying prion candidates (42, 46), they are not sufficient to discriminate among these candidates.

Likewise, although the hidden Markov model of Alberti et al. was extremely effective at identifying prion candidates, it was not effective at predicting which of the top-ranking candidates would have prion-like activity. There was modest correlation between a peptide's ranking for compositional similarity to known PFDs and its prion-like activity, as scored by Alberti et al. based on performance in their four assays (Fig. 8B). The 50 domains with the greatest compositional similarities to known prions showed higher average prion-like activity than those that ranked 51 to 100. However, this algorithm was completely ineffective at ranking these top 50 proteins. Among the 50 highest-scoring domains, there was essentially no correlation between ranking and prion-like activity (correlation coefficient = 0.015 and  $P = 0.96$  by Spearman's rank analysis).

Our algorithm was much more effective at discriminating among these potential PFDs. We scanned each of the 100 domains using a 41-amino-acid window size, identifying for each domain the 41 consecutive 41-amino-acid windows that had the greatest predicted prion propensity while also having an average negative FoldIndex score (i.e., the most prion-prone disordered region). There was a strong correlation be-




FIG. 8. Ranking of Q/N-rich domains based on composition. (A) Box-and-whiskers plot of the prevalence of various amino acids among each of the domains shown by Alberti et al. (1) to have prion-like activity in four prion assays, the domains that lacked prion-like activity in all four prion assays, and the known PFDs. (B) Plot of compositional similarity to known PFDs versus prion-like activity. Alberti et al. (1) ranked the 100 domains with greatest compositional similarity to known yeast PFDs and then tested each domain for prion-like activity in four assays. Prion-like activity was scored on a scale from 0 to 10 (with 10 reflecting full prion-like activity in all four assays). Domains that were not testable in one or more assays are excluded. Known PFDs are indicated with open diamonds. Rank correlation and  $P$  values were calculated by Spearman's rank analysis. (C) Plot of predicted prion propensity versus prion-like activity. For each of the domains tested by Alberti et al., prion propensity was calculated as the 41 consecutive 41-amino-acid windows with maximum average predicted prion propensity that also had a negative FoldIndex order propensity.

tween predicted prion propensity using our algorithm and prion activity (Fig. 8C). Our top 15 ranked domains (from Pub1, Nrp1, Rnq1, New1, YBR016W, YPL184C, Jsn1, Lsm4, Ngr1, Ure2, Cbk1, Mot3, Sok2, YBL081W, and Sup35) had an average score of 8.1 on the 10-point prion-like activity scale of Alberti et al., with all but one scoring at least 5 out of 10 (the one exception, Jsn1, scored 4 out of 10). Additionally, all six domains that scored 10 out of 10 ranked in our top 15. In contrast, the 15 domains with the greatest compositional similarities to known PFDs (as ranked by Alberti et al., excluding domains that were not testable in one or more experiments) had an average score of 5.3; this group included only three of the proteins that scored 10 out of 10 and included six that scored below 5 out of 10. Together, these data demonstrate that our algorithm is much more effective at predicting prion-like activities of Q/N-rich proteins than algorithms that solely utilize compositional similarity to known yeast PFDs.

## DISCUSSION

Although algorithms designed to identify proteins that are compositionally similar to known PFDs have been effective at identifying prion candidates (1, 19, 28, 42, 46), none of these algorithms has proven effective at distinguishing between Q/N-rich proteins that can form prions and those that cannot. Our results explain the basis for this failure. The major flaw in composition-based searches is that they are unable to predict how deviations from the observed biases in known PFDs will affect prion propensity. For example, charged and hydrophobic residues are both underrepresented in yeast PFDs. However, our data suggest very different reasons for these biases; charged residues inhibit prion formation, while hydrophobic residues too strongly promote prion formation and/or order. Accurate prediction of prion propensity requires understanding which deviations from known prion-forming compositions will promote prion formation and which will inhibit it.

To allow accurate prediction of prion propensity, we have developed a method of measuring the prion propensities of individual amino acids *in vivo*. Our mutagenesis uncovered three significant findings: a strong bias against prolines and charged residues, a strong bias for hydrophobic residues, and no significant bias for or against Q/N residues. The bias against charged residues is consistent with findings of previous bioinformatic and mutational analyses (12, 19). However, the other two findings were quite surprising. Q/N residues are highly overrepresented in yeast PFDs (19, 28). Similarly, although bioinformatic and mutational analyses suggest that tyrosines may promote prion formation or propagation (2, 19), hydrophobic residues in general are highly underrepresented in yeast PFDs (19, 28).

Consequently, there was almost no correlation between the experimentally determined prion propensity for a given amino acid and its prevalence within the known PFDs. Thus, we hypothesize that the yeast PFDs are not optimized for maximum intrinsic amyloid propensity but instead that their compositions reflect a balance of intrinsic disorder and prion propensity. While the presence of a small number of additional hydrophobic residues within the Sup35-27 PFD promotes prion formation, larger numbers would likely lead to hydrophobic collapse, potentially inhibiting prion formation or lead-

ing to nonspecific aggregation. Therefore, although the effects of individual mutations within a Q/N-rich domain can be accurately predicted based on hydrophobicity and  $\beta$ -sheet propensity (equation 4), it is necessary to consider order propensity when examining the composition of entire domains. This hypothesis provides a possible explanation for the prevalence of Qs and Ns in the yeast PFDs. Qs and Ns have a relatively high prion propensity compared to other disorder-promoting residues. Alternatively, there may be a threshold number and/or density of Q/N residues required for prion formation, and above this threshold small changes in the number of Q/N residues may exert only a subtle effect.

Based on the apparent importance of intrinsic disorder for yeast PFDs, we propose that amyloid proteins can be divided into three broad classes. First are proteins such as transthyretin (21). These proteins have highly amyloid-prone regions that are usually involved in stable interactions within the folded structure of the protein. As seen in Fig. 6A, regions of high amyloid propensity are common but are generally found in regions predicted to be ordered. For these proteins, native state stability will largely determine amyloid propensity (21). This may explain why a recent genome-wide analysis of *Escherichia coli* proteins found little correlation between the aggregation propensity and the content of hydrophobic residues (31); hydrophobic residues will have competing effects, increasing the intrinsic aggregation propensity while also preventing aggregation by stabilizing the native fold of the protein. Second are non-Q/N-rich disordered peptides such as A $\beta$ , where amyloid formation is driven by short, highly amyloidogenic nucleation domains (3, 34). Third are the Q/N-rich amyloid proteins. Rather than having a high concentration of strongly amyloidogenic (but also order-promoting) residues, the yeast PFDs form prions by excluding order-promoting residues and by having large stretches with a high concentration of the most amyloidogenic disorder-promoting residues. Thus, yeast PFDs do not have to overcome native-state stability to form prions, explaining their efficient prion formation despite their relatively low prion propensity.

Differences between classes of amyloid proteins explain why most amyloid prediction algorithms (developed based on non-Q/N-rich proteins) fail to predict amyloid formation by Q/N-rich proteins, such as the yeast PFDs or expanded polyglutamine tracts. These algorithms are designed to identify the short, highly amyloid-prone segments thought to characterize most amyloid domains (16), not the large disordered segments with modest prion propensity that characterize yeast PFDs.

Although our results support a dominant role for amino acid composition in driving prion formation, they also point to subtle effects of primary sequence. Our algorithm directly incorporates one primary sequence feature: proline patterns. Excluding proline patterning from our algorithm modestly reduces the correlation between the predicted prion propensity and prion-like activity in Fig. 8C from 0.73 to 0.70 (data not shown); however, we are still able to distinguish between Q/N-rich domains that show prion-like activity and those that do not with a high degree of accuracy, and only one of the potential PFDs in Fig. 6C changes from being scored as prion positive to prion negative or vice versa—Mca1, which is scored as barely negative without proline patterning and barely positive with it






FIG. 9. Among domains that are compositionally similar to known yeast PFDs, high glutamine content is correlated with high proline content. (A) For each of the 100 domains tested by Alberti et al., glutamine content was plotted versus the predicted prion propensity (calculated as for Fig. 6C). Rank correlation and  $P$  values were calculated by Spearman's rank analysis. (B) Asparagine content plotted versus predicted prion propensity. (C) Glutamine content plotted versus proline content. (D) Asparagine content plotted versus proline content.

(data not shown). Therefore, 34 of 39 potential PFDs in Fig. 6C are correctly scored based on composition alone.

Because our algorithm allows for reasonably accurate predictions based solely on composition, examination of outlier proteins not accurately predicted by our algorithm may reveal other primary sequence features that affect prion formation. For example, the only known PFD wrongly categorized as nonprion by our algorithm, Cyc8, contains the repeat sequence (AQ)<sub>22</sub>. Alternating polar and nonpolar residues have been shown to promote amyloid formation (5, 59, 60), although alanine has not generally been included among the nonpolar residues when such patterns are considered. Therefore, further studies will be needed to address the role of such repeat sequences in prion formation and potentially to find ways to incorporate such patterns into our algorithm.

Finally, a remarkable finding of Alberti et al. was that among the 100 potential PFDs that they tested, although asparagines were highly enriched among the domains that showed prion-like activity, glutamines were more prevalent in nonaggregating domains (1). The simplest explanation for this difference is that asparagines are more prion prone than glutamines. However, our data point to an alternative reason why asparagine residues may appear to be more positively correlated with prion propensity. Consistent with the experimental findings of Alberti et al., among the 100 potential PFDs there is a strong positive correlation between our predicted prion propensity and asparagine content but a modest negative correlation between predicted prion propensity and glutamine content (Fig. 9A and B). Because glutamine and asparagine have nearly identical prion propensities in our formula, the significant difference in predicted prion propensity between Q-rich and N-rich domains must result from some feature of the tested domains other than Q/N content. Indeed, it results largely

from differences in the prevalence of prolines in Q-rich versus N-rich sequences. Among the tested sequences, glutamine content is strongly correlated with proline content (Fig. 9C) while asparagine content is negatively correlated with proline content (Fig. 9D). Thus, although asparagine may be modestly more prion prone than glutamine (asparagine was modestly favored in library 2), the observed differences between glutamines and asparagines at least in part reflect an artifact of the context in which these residues are found among the tested sequences.

Overall, our data provide detailed insight into how amino acid composition affects prion formation by Q/N-rich domains. By highlighting the critical role for intrinsic disorder in yeast prion formation, our data explain the discrepancies between the compositions of the yeast PFDs and the amino acids thought to promote amyloid formation. Our data will allow genome scanning to accurately identify novel PFDs and to identify critical nucleating domains within known PFDs.

#### ACKNOWLEDGMENTS

We thank Reed Wickner, Olve Peersen, P. Shing Ho, Frank Shewmaker, Kevin Hatcher-Ross, and members of the Ross laboratory for helpful discussion and Nathan Liss, Holly Hamilton, and Daniel Lee for their tireless help in screening thousands of colonies.

This work was funded in part by an American Heart Association grant (0735321N) to E.D.R.

#### REFERENCES

1. Alberti, S., R. Halfmann, O. King, A. Kapila, and S. Lindquist. 2009. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. *Cell* **137**:146–158.
2. Alexandrov, I. M., A. B. Vishnevskaya, M. D. Ter-Avanesyan, and V. V. Kushnirov. 2008. Appearance and propagation of polyglutamine-based amyloids in yeast: tyrosine residues enable polymer fragmentation. *J. Biol. Chem.* **283**:15185–15192.
3. Balbach, J. J., Y. Ishii, O. N. Antzutkin, R. D. Leapman, N. W. Rizzo, F. Dyda, J. Reed, and R. Tycko. 2000. Amyloid fibril formation by A beta 16–22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid state NMR. *Biochemistry* **39**:13748–13759.
4. Bradley, M. E., and S. W. Liebman. 2004. The Sup35 domains required for maintenance of weak, strong or undifferentiated yeast [PSI<sup>+</sup>] prions. *Mol. Microbiol.* **51**:1649–1659.
5. Broome, B. M., and M. H. Hecht. 2000. Nature disfavors sequences of alternating polar and non-polar amino acids: implications for amyloidogenesis. *J. Mol. Biol.* **296**:961–968.
6. Bryan, A. W., Jr., M. Menke, L. J. Cowen, S. L. Lindquist, and B. Berger. 2009. BETASCAN: probable beta-amyloids identified by pairwise probabilistic analysis. *PLoS Comput. Biol.* **5**:e1000333.
7. Chang, H. Y., J. Y. Lin, H. C. Lee, H. L. Wang, and C. Y. King. 2008. Strain-specific sequences required for yeast [PSI<sup>+</sup>] prion propagation. *Proc. Natl. Acad. Sci. U. S. A.* **105**:13345–13350.
8. Chiti, F., and C. M. Dobson. 2006. Protein misfolding, functional amyloid, and human disease. *Annu. Rev. Biochem.* **75**:333–366.
9. Chou, P. Y., and G. D. Fasman. 1974. Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins. *Biochemistry* **13**:211–222.
10. Chou, P. Y., and G. D. Fasman. 1978. Empirical predictions of protein conformation. *Annu. Rev. Biochem.* **47**:251–276.
11. Cox, B. S. 1965. PSI, a cytoplasmic suppressor of super-suppressor in yeast. *Heredity* **26**:211–232.
12. DePace, A. H., A. Santoso, P. Hillner, and J. S. Weissman. 1998. A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion. *Cell* **93**:1241–1252.
13. Derkatch, I. L., M. E. Bradley, J. Y. Hong, and S. W. Liebman. 2001. Prions affect the appearance of other prions: the story of [PIN(+)]. *Cell* **106**:171–182.
14. Derkatch, I. L., Y. O. Chernoff, V. V. Kushnirov, S. G. Inge-Vechtomov, and S. W. Liebman. 1996. Genesis and variability of [PSI] prion factors in *Saccharomyces cerevisiae*. *Genetics* **144**:1375–1386.
15. Du, Z., K. W. Park, H. Yu, Q. Fan, and L. Li. 2008. Newly identified prion linked to the chromatin-remodeling factor Swi1 in *Saccharomyces cerevisiae*. *Nat. Genet.* **40**:460–465.

16. **Esteras-Chopo, A., L. Serrano, and M. L. de la Paz.** 2005. The amyloid stretch hypothesis: recruiting proteins toward the dark side. *Proc. Natl. Acad. Sci. U. S. A.* **102**:16672–16677.
17. **Fernandez-Escamilla, A. M., F. Rousseau, J. Schymkowitz, and L. Serrano.** 2004. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. *Nat. Biotechnol.* **22**:1302–1306.
18. **Ferreira, P. C., F. Ness, S. R. Edwards, B. S. Cox, and M. F. Tuite.** 2001. The elimination of the yeast [PSI<sup>+</sup>] prion by guanidine hydrochloride is the result of Hsp104 inactivation. *Mol. Microbiol.* **40**:1357–1369.
19. **Harrison, P. M., and M. Gerstein.** 2003. A method to assess compositional bias in biological sequences and its application to prion-like glutamine/asparagine-rich domains in eukaryotic proteomes. *Genome Biol.* **4**:R40.
20. **Jung, G., and D. C. Masison.** 2001. Guanidine hydrochloride inhibits Hsp104 activity in vivo: a possible explanation for its effect in curing yeast prions. *Curr. Microbiol.* **43**:7–10.
21. **Kelly, J. W.** 1998. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. *Curr. Opin. Struct. Biol.* **8**:101–106.
22. **Koehl, P., and M. Levitt.** 1999. Structure-based conformational preferences of amino acids. *Proc. Natl. Acad. Sci. U. S. A.* **96**:12524–12529.
23. **Kushnirov, V. V., and M. D. Ter-Avanesyan.** 1998. Structure and replication of yeast prions. *Cell* **94**:13–16.
24. **Linding, R., J. Schymkowitz, F. Rousseau, F. Diella, and L. Serrano.** 2004. A comparative study of the relationship between protein structure and [beta]-aggregation in globular and intrinsically disordered proteins. *J. Mol. Biol.* **342**:345–353.
25. **Masel, J., and C. K. Griswold.** 2009. The strength of selection against the yeast prion [PSI<sup>+</sup>]. *Genetics* **181**:1057–1063.
26. **Masison, D. C., M. L. Maddelein, and R. B. Wickner.** 1997. The prion model for [URE3] of yeast: spontaneous generation and requirements for propagation. *Proc. Natl. Acad. Sci. U. S. A.* **94**:12503–12508.
27. **Masison, D. C., and R. B. Wickner.** 1995. Prion-inducing domain of yeast Ure2p and protease resistance of Ure2p in prion-containing cells. *Science* **270**:93–95.
28. **Michelitsch, M. D., and J. S. Weissman.** 2000. A census of glutamine/asparagine-rich regions: implications for their conserved function and the prediction of novel prions. *Proc. Natl. Acad. Sci. U. S. A.* **97**:11910–11915.
29. **Nakayashiki, T., C. P. Kurtzman, H. K. Edskes, and R. B. Wickner.** 2005. Yeast prions [URE3] and [PSI<sup>+</sup>] are diseases. *Proc. Natl. Acad. Sci. U. S. A.* **102**:10575–10580.
30. **Nemecek, J., T. Nakayashiki, and R. B. Wickner.** 2009. A prion of yeast metacaspase homolog (Mca1p) detected by a genetic screen. *Proc. Natl. Acad. Sci. U. S. A.* **106**:1892–1896.
31. **Niwa, T., B. W. Ying, K. Saito, W. Jin, S. Takada, T. Ueda, and H. Taguchi.** 2009. Bimodal protein solubility distribution revealed by an aggregation analysis of the entire ensemble of *Escherichia coli* proteins. *Proc. Natl. Acad. Sci. U. S. A.* **106**:4201–4206.
32. **Osherovich, L. Z., B. S. Cox, M. F. Tuite, and J. S. Weissman.** 2004. Dissection and design of yeast prions. *PLoS Biol.* **2**:E86.
33. **Patel, B. K., J. Gavin-Smyth, and S. W. Liebman.** 2009. The yeast global transcriptional co-repressor protein Cyc8 can propagate as a prion. *Nat. Cell Biol.* **11**:344–349.
34. **Pawar, A. P., K. F. Dubay, J. Zurdo, F. Chiti, M. Vendruscolo, and C. M. Dobson.** 2005. Prediction of “aggregation-prone” and “aggregation-susceptible” regions in proteins associated with neurodegenerative diseases. *J. Mol. Biol.* **350**:379–392.
35. **Perutz, M. F., B. J. Pope, D. Owen, E. E. Wanker, and E. Scherzinger.** 2002. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. *Proc. Natl. Acad. Sci. U. S. A.* **99**:5596–5600.
36. **Peters, T. W., and M. Huang.** 2007. Protein aggregation and polyasparagine-mediated cellular toxicity in *Saccharomyces cerevisiae*. *Prion* **1**:144–153.
37. **Pierce, M. M., U. Baxa, A. C. Steven, A. Bax, and R. B. Wickner.** 2005. Is the prion domain of soluble Ure2p unstructured? *Biochemistry* **44**:321–328.
38. **Prilusky, J., C. E. Felder, T. Zeev-Ben-Mordehai, E. H. Rydberg, O. Man, J. S. Beckmann, I. Silman, and J. L. Sussman.** 2005. FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded. *Bioinformatics* **21**:3435–3438.
39. **Roseman, M. A.** 1988. Hydrophilicity of polar amino acid side-chains is markedly reduced by flanking peptide bonds. *J. Mol. Biol.* **200**:513–522.
40. **Ross, E. D., U. Baxa, and R. B. Wickner.** 2004. Scrambled prion domains form prions and amyloid. *Mol. Cell. Biol.* **24**:7206–7213.
41. **Ross, E. D., H. K. Edskes, M. J. Terry, and R. B. Wickner.** 2005. Primary sequence independence for prion formation. *Proc. Natl. Acad. Sci. U. S. A.* **102**:12825–12830.
42. **Santoso, A., P. Chien, L. Z. Osherovich, and J. S. Weissman.** 2000. Molecular basis of a yeast prion species barrier. *Cell* **100**:277–288.
43. **Serio, T. R., A. G. Cashikar, A. S. Kowal, G. J. Sawicki, J. J. Moslehi, L. Serpell, M. F. Arnsdorf, and S. L. Lindquist.** 2000. Nucleated conformational conversion and the replication of conformational information by a prion determinant. *Science* **289**:1317–1321.
44. **Sherman, F.** 1991. Getting started with yeast. *Methods Enzymol.* **194**:3–21.
45. **Shewmaker, F., E. D. Ross, R. Tycko, and R. B. Wickner.** 2008. Amyloids of shuffled prion domains that form prions have a parallel in-register beta-sheet structure. *Biochemistry* **47**:4000–4007.
46. **Sondheimer, N., and S. Lindquist.** 2000. Rnq1: an epigenetic modifier of protein function in yeast. *Mol. Cell* **5**:163–172.
47. **Song, Y., Y. X. Wu, G. Jung, Y. Tutar, E. Eisenberg, L. E. Greene, and D. C. Masison.** 2005. Role for Hsp70 chaperone in *Saccharomyces cerevisiae* prion seed replication. *Eukaryot. Cell* **4**:289–297.
48. **Street, A. G., and S. L. Mayo.** 1999. Intrinsic beta-sheet propensities result from van der Waals interactions between side chains and the local backbone. *Proc. Natl. Acad. Sci. U. S. A.* **96**:9074–9076.
49. **Taneja, V., M. L. Maddelein, N. Talarek, S. J. Saupé, and S. W. Liebman.** 2007. A non-Q/N-rich prion domain of a foreign prion, [Het-], can propagate as a prion in yeast. *Mol. Cell* **27**:67–77.
50. **Tank, E. M., D. A. Harris, A. A. Desai, and H. L. True.** 2007. Prion protein repeat expansion results in increased aggregation and reveals phenotypic variability. *Mol. Cell. Biol.* **27**:5445–5455.
51. **Tartaglia, G. G., A. P. Pawar, S. Campioni, C. M. Dobson, F. Chiti, and M. Vendruscolo.** 2008. Prediction of aggregation-prone regions in structured proteins. *J. Mol. Biol.* **380**:425–436.
52. **Ter-Avanesyan, M. D., A. R. Dagkesamanskaya, V. V. Kushnirov, and V. N. Smirnov.** 1994. The SUP35 omnipotent suppressor gene is involved in the maintenance of the non-Mendelian determinant [psi<sup>+</sup>] in the yeast *Saccharomyces cerevisiae*. *Genetics* **137**:671–676.
53. **Ter-Avanesyan, M. D., V. V. Kushnirov, A. R. Dagkesamanskaya, S. A. Didichenko, Y. O. Chernoff, S. G. Inge-Vechtomov, and V. N. Smirnov.** 1993. Deletion analysis of the SUP35 gene of the yeast *Saccharomyces cerevisiae* reveals two non-overlapping functional regions in the encoded protein. *Mol. Microbiol.* **7**:683–692.
54. **Toyama, B. H., M. J. Kelly, J. D. Gross, and J. S. Weissman.** 2007. The structural basis of yeast prion strain variants. *Nature* **449**:233–237.
55. **Trovato, A., F. Seno, and S. C. Tosatto.** 2007. The PASTA server for protein aggregation prediction. *Protein Eng. Des. Sel.* **20**:521–523.
56. **True, H. L., and S. L. Lindquist.** 2000. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. *Nature* **407**:477–483.
57. **Tuite, M. F., C. R. Mundy, and B. S. Cox.** 1981. Agents that cause a high frequency of genetic change from [psi<sup>+</sup>] to [psi<sup>-</sup>] in *Saccharomyces cerevisiae*. *Genetics* **98**:691–711.
58. **Weathers, E. A., M. E. Paulaitis, T. B. Woolf, and J. H. Hoh.** 2004. Reduced amino acid alphabet is sufficient to accurately recognize intrinsically disordered protein. *FEBS Lett.* **576**:348–352.
59. **West, M. W., and M. H. Hecht.** 1995. Binary patterning of polar and non-polar amino acids in the sequences and structures of native proteins. *Protein Sci.* **4**:2032–2039.
60. **West, M. W., W. Wang, J. Patterson, J. D. Mancias, J. R. Beasley, and M. H. Hecht.** 1999. De novo amyloid proteins from designed combinatorial libraries. *Proc. Natl. Acad. Sci. U. S. A.* **96**:11211–11216.
61. **Wickner, R. B.** 1994. [URE3] as an altered URE2 protein: evidence for a prion analog in *Saccharomyces cerevisiae*. *Science* **264**:566–569.
62. **Zibae, S., O. S. Makin, M. Goedert, and L. C. Serpell.** 2007. A simple algorithm locates beta-strands in the amyloid fibril core of alpha-synuclein, Abeta, and tau using the amino acid sequence alone. *Protein Sci.* **16**:906–918.
63. **Zoghbi, H. Y., and H. T. Orr.** 2000. Glutamine repeats and neurodegeneration. *Annu. Rev. Neurosci.* **23**:217–247.